scholarly journals Effect of Astaxanthin on cell viability in T-47D and MDA-MB-231 Breast Cancer Cell Lines

2017 ◽  
Vol 1 (Supplementary 1) ◽  
pp. 0-0 ◽  
Author(s):  
Aida Karimian ◽  
Mohammad Hadi Bahadori ◽  
Akbar Hajizadeh Moghaddam ◽  
Fereshteh Mir Mohammadrezaei
1993 ◽  
Vol 28 (1) ◽  
pp. 21-27 ◽  
Author(s):  
Ossi R. Koechli ◽  
Bernd-Uwe Sevin ◽  
James P. Perras ◽  
Ting Chao Chou ◽  
Roberto Angioli ◽  
...  

Author(s):  
Abd Elmoneim O. Elkhalifa ◽  
Eyad Al-Shammari ◽  
Mohammad Jahoor Alam ◽  
Jerold C. Alcantara ◽  
Mushtaq Ahmad Khan ◽  
...  

Objective: Cancer chemoprevention with phytochemicals such as “lutein” derived from the vegetable okra could prove beneficial. Therefore, the objective of this study was to perform a meta-analysis of “lutein” against the breast cancer cell lines (MCF-7) and to establish the possible development of lutein based nutraceuticals. Methodology: A literature survey was performed using online data bases such as PubMed, Google scholar, and EMBASE, from 2000 to 2020 by using keywords such as “Lutein”, “Anticancer activity”, “Breast cancer cell lines”, and “MCF-7”. Studies reported lutein anticancer potentials against MCF-7 were included in the study. Results: Out of 28 studies, 7 research articles fulfilled the inclusion criteria. Meta-analysis data indicated that, a lutein concentration at ≥1 µM was able to reduce the MCF-7 cell viability of 59.837 with a 95% confidence interval (CI): 48.331 to 71.343. Additionally, a forest plot of the cumulative studies also indicated that impact of lutein concentration to reduce the MCF-7 cell viability was around 60%. Moreover, the I2 value of lutein was 74%, which is a considerable heterogeneity. Conclusion: Therefore, based upon the meta-analysis data, the conclusion is that dietary lutein supplementation and fortification of food with clinical data could be an approach to develop a nutraceutical product for preventive, as well as for adjunct therapeutic purposes in various breast cancer subtypes. 


2008 ◽  
Vol 197 (3) ◽  
pp. 517-529 ◽  
Author(s):  
Sanda Raulic ◽  
Yudith Ramos-Valdes ◽  
Gabriel E DiMattia

Stanniocalcin 1 (STC1) and STC2 are secreted, homodimeric glycoproteins that share 30% amino acid sequence identity. Breast tumour gene profiling studies have demonstrated significantly upregulated STC2 expression in hormone-responsive positive breast tumours; therefore, the purpose of this study was to investigate STC2 hormonal regulation and function in breast cancer cells. Here we report that STC2 is expressed in a number of human breast cancer cell lines, regardless of their oestrogen (E2) and progesterone (P4) receptor status, and its expression is readily detectable in human and mouse mammary gland tumours. Besides E2, retinoic acid (RA) and P4 play an important role in the regulation of STC2 expression, not only in MCF-7 but also in other breast cancer and non-breast cell lines. The expression of the related hormone, STC1, is not affected by the above hormones in breast and endometrial cancer cell lines implying a fundamental difference in regulation in cancer cell lines. The induction of STC2 expression by E2 and RA occurs at the transcriptional level but through intermediary transcription factors. The STC2 proximal promoter region is not responsible for hormonal induction, but exhibits a high basal transcriptional activity. Constitutive STC2 expression in human breast cancer cell lines resulted in significant impairment of cell growth, migration and cell viability after serum withdrawal. In conclusion, STC2 is a downstream target of E2, P4 and RA signalling pathways. In hormone receptor negative cell lines it can function in a paracrine/autocrine fashion to reduce cell proliferation.


1994 ◽  
Vol 5 (1) ◽  
pp. 24-30 ◽  
Author(s):  
Michael Untch ◽  
Andrea Untch ◽  
Bernd-Uwe Sevin ◽  
Roberto Angioli ◽  
James P Perras ◽  
...  

2018 ◽  
Vol 8 (3) ◽  
pp. 159 ◽  
Author(s):  
Meghan Fragis ◽  
Abdulmonem I. Murayyan ◽  
Suresh Neethirajan

Background: Breast cancer is the most commonly diagnosed cancer and the second leading cause of cancer deaths among Canadian women. Cancer management through changes in lifestyle, such as increased intake of foods rich in dietary flavonoids, have been shown to decrease the risk associated with breast, liver, colorectal, and upper-digestive cancers in epidemiologic studies. Onions are high in flavonoid content and one of the most common vegetables. Additionally, onions are used in most Canadian cuisines.Methods: We investigated the effect of five prominent Ontario grown onion (Stanley, Ruby Ring, LaSalle, Fortress, and Safrane) extracts on two subtypes of breast cancer cell lines: a triple negative breast cancer line MDA-MB-231 and an ER+ breast cancer line MCF-7.Results: These onion extracts elicited strong anti-proliferative, anti-migratory, and cytotoxic activities on both the cancer cell lines. Flavonoids present in these onion extracts induced apoptosis, cell cycle arrest in the G2/M phase, and a reduction in mitochondrial membrane potential at dose-dependent concentrations. Onion extracts were more effective against MDA-MB-231 compared to the MCF-7 cell line. Conclusion: In this study, we investigated the extracts synthesized from Ontario-grown onion varieties in inducing anti-migratory, cytostatic, and cytotoxic activities in two sub-types of human breast cancer cell lines. Anti-tumor activity of these extracts depends upon the varietal and can be formulated into nutraceuticals and functional foods for the wellbeing of cancer patients. Overall, the results suggest that onion extracts are a good source of flavonoids with anti-cancerous properties.Keywords: onion extracts; flavonoids; anti-proliferative; breast cancer; cytotoxic activity


Sign in / Sign up

Export Citation Format

Share Document